Four of six NSQ NSCLC trials demonstrated significant OS benefit with addition of a PD-1 inhibitor to chemotherapy among the entire population (not significant in CheckMate 227 Part 2 and not reported in RATIONALE 304), and PFS benefit reported in all six trials. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.